Disclaimer: This article is for informational and entertainment purposes only. We do not endorse or recommend the use of weight-loss drugs such as Ozempic, Wegovy, or similar GLP-1 medications. While these drugs may show promise in some clinical contexts, they also carry potential risks and side effects. Our philosophy strongly supports achieving long-term health through balanced nutrition, consistent exercise, and sustainable lifestyle habits. Always consult with a healthcare professional before considering any medical treatment for weight loss.
As revolutionary weight-loss drugs like Ozempic shift Americans’ taste preferences away from ultraprocessed snacks, Big Food is scrambling to reinvent itself. But can it outsmart biology again?
A quiet revolution is unfolding in supermarket aisles — and it’s not coming from a new fad diet or a flashy wellness trend. It’s coming from a once-obscure class of medications, GLP-1 agonists like Ozempic and Wegovy, which are fundamentally changing how millions of people eat.
As these drugs rapidly gain popularity, they’re not just curbing appetites — they’re rewiring cravings and turning once-devoted junk-food lovers into fresh produce enthusiasts.
And that spells trouble for Big Food.
Jump to:
Appetite for Change: How GLP-1 Drugs Are Reshaping Eating Habits
The rise of drugs like Ozempic, Wegovy, and Zepbound marks a seismic shift in the war on obesity. These GLP-1 agonists mimic a hormone that slows digestion and tells the brain you’re full — with effects that go far beyond hunger suppression.
They’re changing taste.
Many users report a near-total disinterest in the ultraprocessed snacks that once ruled their diets. Products like Doritos, Pop-Tarts, and Hostess cupcakes have gone from irresistible to inedible. For Trinian Taylor, a 52-year-old from California featured in a recent New York Times profile, the switch was dramatic. “It was so sweet it choked me,” he said of candy offered by his daughter. These days, his midnight cravings revolve around cucumbers, kale, and lemon-infused water.
Millions of others are experiencing similar transformations. Morgan Stanley estimates that by 2035, as many as 24 million Americans will be on GLP-1 drugs — more than twice the number of vegetarians and vegans combined.
And unlike previous diet trends, this one is driven not by willpower, but by neurochemistry.
A Crisis of Cravings for Big Food
For decades, ultraprocessed foods thrived by hijacking the brain’s reward system. Layers of salt, sugar, and fat hit the dopamine centers like a slot machine. But now, GLP-1s appear to be turning down the volume on those neural fireworks.
“They’re scared about it,” Novo Nordisk CEO Lars Fruergaard Jorgensen told Bloomberg, referring to food-industry executives.
There’s reason to be.
Walmart’s U.S. CEO confirmed that shoppers on GLP-1s are buying less food. Sales of sweet snacks and baked goods are dipping. One market research firm even reported that food-and-beverage innovation hit an all-time low in 2024.
And it’s not just about eating less. It’s about eating differently.
Focus groups organized by food-innovation firm Mattson found that Ozempic users are falling in love with simple, whole foods. A 69-year-old who once lived off fast food now heads straight to the produce aisle. A 32-year-old chemist described rediscovering the natural flavors of celery and strawberries. For many, ultraprocessed foods no longer taste like food at all — they taste like chemicals.
“I just started to realize that they taste wonderful by themselves,” the chemist said of whole foods.
Big Food’s Pivot: From Bliss Points to Satiety Science
Big Food is famous for adapting. When fat-free diets were in vogue, it flooded the market with SnackWell’s and Lean Cuisines. When low-carb hit, it bought into Atkins. When protein became the buzzword, everything from cereal to yogurt got a muscle-building makeover.
Now, it’s pivoting again — toward GLP-1-friendly foods.
Nestlé is rolling out Vital Pursuit, a line of frozen meals tailored to smaller appetites and protein needs. Coca-Cola’s Fairlife protein shakes are gaining traction on GLP-1 forums. Mattson itself is developing “NourishFit” brownie bites with whey protein, no-carb tacos made with endive leaves, and even satiety-enhancing chewing gum.
The goal: convenience and nutrition in forms that don’t trigger revulsion in GLP-1 users.
“These are self-limiting products,” said Amanda Sinrod, a senior Mattson food scientist, describing the bite-sized, protein-packed snacks. “Portions could be packaged individually.”
Mattson’s strategy is clear — if GLP-1s are turning off the “industrial palate,” then maybe industrial food just needs to evolve.
Can Science Override the Brain’s New Rules?
There’s a catch: GLP-1 drugs don’t just dull appetite — they appear to modulate reward itself.
These medications affect the dopamine system, the same one targeted by addictive drugs, junk food, and even gambling. This may be why patients report reduced cravings not only for food, but also for alcohol, nicotine, and even cocaine.
So the question becomes: Can food companies outmaneuver a medication that’s literally rewiring desire?
Some scientists are skeptical. Ashley Gearhardt, a psychology professor and food-addiction researcher, says the drugs are still a “black box.” But others warn that food companies — armed with decades of flavor science — could theoretically create compounds that counteract GLP-1 effects.
“It’s plausible,” said Nicole Avena, a Mount Sinai neuroscientist who studies sugar addiction. The industry, she notes, has long specialized in pushing biological buttons.
The Future of Food: Clean Labels or Clever Tweaks?
Despite its fraught history, the food industry isn’t giving up. It’s betting that people still want convenience — even if they’re only eating a few bites.
“People are not going to want to prep an elaborate meal to eat just a small amount,” said Bob Nolan of Conagra Brands, which owns Healthy Choice.
Mattson’s CEO, Justin Shimek, believes in this vision — personally. After decades of struggling with weight, he began taking a GLP-1 drug and lost 50 pounds. His cravings, he says, are gone.
But Shimek is also optimistic. “Taste and pleasure are very important,” he says, “but not the only thing.”
If Big Food can offer satisfying, nutrient-rich, low-calorie options that align with the new biology of GLP-1 users, it may survive this disruption. But if it tries to outsmart the drugs with more dopamine-boosting tricks, it risks alienating an emerging majority.
Final Bite: Will Convenience Conquer Again?
The rise of GLP-1s may be the most profound challenge the food industry has ever faced. Not because people are choosing to eat differently — but because they’re no longer wired to crave the foods that once made billions.
Can Mattson’s high-protein brownie bites, freeze-dried soups, and satiety gums replace Rainier cherries and fresh salads in the hearts of GLP-1 users?
Maybe. But for now, the supermarket sweet spot lies somewhere between the produce section and the protein aisle — and it’s a space that junk food is struggling to fill.
